Updated October 25, 2026 · Sources linked below
GLP-1-based medicines have changed obesity treatment, but choosing one still requires an individual medical assessment. The right starting point is the condition being treated, the specific approved product, and the balance of expected benefit, risks, and practical access.
These medicines are not interchangeable with every product advertised as a “weight-loss peptide.” Tirzepatide also acts at the GIP receptor, while semaglutide is a GLP-1 receptor agonist. Indications and prescribing details differ by product. [1]
Who may be considered for treatment?
General adult weight-management criteria often include obesity, or overweight with a weight-related condition. Meeting a threshold does not automatically make a particular medicine suitable. The assessment also considers medical and family history, current medicines, previous treatment response, pregnancy plans, and the product’s contraindications and warnings. [1]
A clinician should explain alternatives as well as the proposed treatment. Nutrition, suitable activity, behavioral support, and sometimes metabolic surgery are parts of the broader care landscape.
What should follow-up include?
Follow-up should assess response, side effects, eating adequacy, hydration when relevant, and practical barriers. Ask how treatment will be adjusted, what to do after a missed dose, and which symptoms require prompt contact. Obtain instructions for your exact medication rather than borrowing a schedule from another person.
Ask where the medicine comes from and whether it is an FDA-approved product. FDA warns that unapproved versions have not undergone its premarket review for safety, effectiveness, and quality. Compounded products are not FDA-approved and are not automatically equivalent to approved medicines. [2]
Think beyond the first months
The initial weight-loss phase is only part of treatment. Maintenance, affordability, access, and tolerability all affect long-term decisions. A structured program should explain how these will be reviewed. [3]
If the scale stops changing, review the pattern before concluding that the medication has stopped providing benefit. If treatment must end, discuss a transition plan rather than waiting for an unexpected interruption.
Are all GLP-1 medicines approved for weight management?
No. Approval is product- and indication-specific. A familiar ingredient name does not establish that every formulation or use is approved.
Is retatrutide another routine option?
It remains an investigational research topic as of October 25, 2026. FDA states that it cannot be used in compounding. Learning about its trials is different from offering it as available treatment. [2]
What should I bring to a Milton consultation?
Bring your medication and supplement list, previous weight-management history, relevant results, and goals. Ask for a written follow-up and safety plan.
Sources and further reading
- NIDDK: prescription medications to treat overweight and obesity
- FDA: concerns with unapproved GLP-1 drugs, including retatrutide and cagrilintide
- NIDDK: choosing a safe and successful weight-loss program
Patient education from OlympusMD Wellness in Milton, Georgia. This article provides general information and does not replace an individual medical evaluation.
